Newly developed preconditioning regimen consisting of rituximab, splenectomy and plasmapheresis for non-responders to conventional regimen in ABO-incompatible kidney transplantation

[1]  K. Stamatopoulos,et al.  Rituximab-associated immune myelopathy. , 2003, Blood.

[2]  P. Solal-Céligny,et al.  Neutropenia in patients treated with rituximab. , 2003, The New England journal of medicine.

[3]  D. Maloney,et al.  Agranulocytosis unresponsive to growth factors following rituximab in vivo purging. , 2003, Blood.

[4]  S. Teraoka,et al.  Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis , 2002, Transplantation.

[5]  L. Rydberg.  ABO‐incompatibility in solid organ transplantation , 2001, Transfusion medicine.

[6]  G. Salles,et al.  Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. , 2001, The hematology journal : the official journal of the European Haematology Association.

[7]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[8]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[9]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. , 1994, Blood.

[10]  J. Squifflet,et al.  Present experiences in a series of 26 ABO-incompatible living donor renal allografts. , 1987, Transplantation proceedings.